GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,990
+140 (0.94%)
Feb 21, 2025, 3:30 PM KST
44.55%
Market Cap 664.13B
Revenue n/a
Net Income n/a
Shares Out 44.30M
EPS n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,014,301
Average Volume 1,265,509
Open 14,850
Previous Close 14,850
Day's Range 14,540 - 15,040
52-Week Range 7,490 - 16,340
Beta n/a
RSI 70.66
Earnings Date n/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Kor... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

News

There is no news available yet.